166MO Datopotamab deruxtecan (Dato-DXd) + durvalumab (D) as first-line (1L) treatment for unresectable locally advanced/metastatic triple-negative breast cancer (a/mTNBC): Initial results from BEGONIA, a phase Ib/II study
Titel:
166MO Datopotamab deruxtecan (Dato-DXd) + durvalumab (D) as first-line (1L) treatment for unresectable locally advanced/metastatic triple-negative breast cancer (a/mTNBC): Initial results from BEGONIA, a phase Ib/II study
Auteur:
Schmid, P. Jung, K.H. Wysocki, P.J. Jassem, J. Ma, C.X. Fernandes, R. Huisden, R. Stewart, R. Vukovic, P. Tablante Nunes, A. Nowecki, Z.